Meda will thus add an anticoagulant, a diuretic, an NSAID drug, and an antidepressant to its portfolio.

Meda acquired four pharmaceutical products from Roche for E120 million, or $176 million. The products have a total sales level of SEK500 million, or $78.4 million, more than half the amount being paid by Meda.

The four acquired Roche products include Marcoumar, an anticoagulant, Torem, a loop diuretic, Tilcotil, an NSAID drug for the treatment of painful inflammatory and degenerative disorders of the musculoskeletal, and Aurorix, an MAO-A inhibitor and antidepressant.

Previous articleAstraZeneca and Singapore Institutions Ally to Develop Drugs for Liver Cancer
Next articleInvestigators Find Gene Signature that Predicts Progression from Stage III to Stage IV Melanoma